IL290619A - Treatment of rms by switching therapy - Google Patents

Treatment of rms by switching therapy

Info

Publication number
IL290619A
IL290619A IL290619A IL29061922A IL290619A IL 290619 A IL290619 A IL 290619A IL 290619 A IL290619 A IL 290619A IL 29061922 A IL29061922 A IL 29061922A IL 290619 A IL290619 A IL 290619A
Authority
IL
Israel
Prior art keywords
treatment
rms
switching
switching treatment
rms treatment
Prior art date
Application number
IL290619A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL290619(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL290619A publication Critical patent/IL290619A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL290619A 2019-09-11 2022-02-14 Treatment of rms by switching therapy IL290619A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19196789 2019-09-11
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Publications (1)

Publication Number Publication Date
IL290619A true IL290619A (en) 2022-04-01

Family

ID=72709332

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290619A IL290619A (en) 2019-09-11 2022-02-14 Treatment of rms by switching therapy

Country Status (15)

Country Link
US (1) US20220298253A1 (cg-RX-API-DMAC7.html)
EP (2) EP3864053B1 (cg-RX-API-DMAC7.html)
JP (2) JP7794735B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062025A (cg-RX-API-DMAC7.html)
CN (3) CN118436777A (cg-RX-API-DMAC7.html)
AU (1) AU2020344154A1 (cg-RX-API-DMAC7.html)
CA (1) CA3150947A1 (cg-RX-API-DMAC7.html)
DK (1) DK3864053T3 (cg-RX-API-DMAC7.html)
ES (1) ES2957112T3 (cg-RX-API-DMAC7.html)
FI (1) FI3864053T3 (cg-RX-API-DMAC7.html)
IL (1) IL290619A (cg-RX-API-DMAC7.html)
LT (1) LT3864053T (cg-RX-API-DMAC7.html)
MX (1) MX2022003010A (cg-RX-API-DMAC7.html)
SI (1) SI3864053T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4252847A3 (en) 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2021204994A1 (en) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg
CA3215371A1 (en) * 2021-04-13 2022-10-20 Shibeshih Mitiku BELACHEW Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
CN117529336A (zh) * 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
EP4252847A3 (en) * 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab

Also Published As

Publication number Publication date
AU2020344154A1 (en) 2022-04-07
EP4230655A2 (en) 2023-08-23
CN114401742A (zh) 2022-04-26
CN118403156A (zh) 2024-07-30
EP3864053B1 (en) 2023-07-05
DK3864053T3 (da) 2023-09-11
JP2026016387A (ja) 2026-02-03
LT3864053T (lt) 2023-09-11
CN114401742B (zh) 2024-05-24
SI3864053T1 (sl) 2023-12-29
CN118436777A (zh) 2024-08-06
MX2022003010A (es) 2022-06-02
US20220298253A1 (en) 2022-09-22
CA3150947A1 (en) 2021-03-18
KR20220062025A (ko) 2022-05-13
EP4230655A3 (en) 2023-11-01
JP7794735B2 (ja) 2026-01-06
FI3864053T3 (fi) 2023-09-13
EP3864053A1 (en) 2021-08-18
WO2021048280A1 (en) 2021-03-18
JP2022548575A (ja) 2022-11-21
ES2957112T3 (es) 2024-01-11

Similar Documents

Publication Publication Date Title
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EP3891771C0 (en) SWITCH
LT3864053T (lt) Rms gydymas, pakeičiant terapiją
EP3999100C0 (en) ENHANCED TREATMENT WITH EYP001
DE112019001011A5 (de) Schaltvorrichtung
DK3546664T3 (da) Vaskebord
DK3722233T3 (da) Transportvejs-omleder
IL280968A (en) Combination therapy
EP3826044C0 (fr) Interrupteur multipolaire
EP4041854C0 (en) FABRIC SOFTENER
EP4041855C0 (en) FABRIC SOFTENER
EP3941217A4 (en) THICKENING COMPOSITION
DK3840144T3 (da) Skifteanordningen
EP4006940A4 (en) Switch
EP3832620C0 (en) MANUAL CALL POINT
DK3738452T3 (da) Fordamper
EP3802308C0 (en) TOGGLE
IL288237A (en) Combination therapy
EP3928337C0 (de) Schaltvorrichtung
EP3986109C0 (en) PLASMA TREATMENT
EP3988334A4 (en) TIRES
EP3988645A4 (en) Decellularization method
EP3967117C0 (en) Feed-through
EP3524862C0 (de) Umschaltvorrichtung
EP3980515C0 (en) ROASTING PROCESS